

This PANNA newsletter will also be available at the website: www.pannastudy.com

A newsletter will be issued regularly to update you on the status of the study and inclusions.

Centres

All centres in *The Netherlands; UK (including satellite sites); Italy; Germany; Belgium; Ireland; Spain* are open for inclusion (including amendment 3).

List of compounds under investigation, still open



panna

Etravirine, Intence, ETV
 Rilpivirine, Edurant, Eviplera
 Abacavir, Ziagen, Kivexa, Trizivir
 Fosamprenavir, Telzir, FPV
 Tipranavir, Aptivus, TPV
 Indinavir, Crixivan, IDV
 Enfuvirtide, Fuzeon, T-20
 Maraviroc, Celsentri, MVC
 Efavirenz, Stocrin, Atripla, EFV*
 *UK/Ireland only

Closed arms:

Tenofovir, emtricitabine, atazanavir, darunavir and raltegravir.

Inclusions



PUBLICATIONS and PLANS

The case report on the first two pregnant patients on rilpivirine has been published by AIDS.

CROI 2014

All three submitted abstracts submitted to CROI have been accepted for poster presentations on Thursday Mar 6 2014 2:30 PM - 4:00 PM (P-T9).

*There will not be an official investigator's meeting, but we would like to invite you for dinner on **Tuesday evening March 4th**. Please let Angela know if you are available. She will keep you updated on the time and location.*

Publications on atazanavir, darunavir and raltegravir are being prepared. Maren Blonk, PhD student of David Burger, will write the raltegravir paper (raltegravir pharmacokinetics will be the subject of her thesis).

Pepe Moltó and Marta Valle are working on a population PK model for darunavir during pregnancy, using the PANNA data.

Physiologically Based PK modelling is being worked on by Angela in collaboration with Rick Greupink of the department of Pharmacology/toxicology of the Radboudumc. The project is called PIANO (Pharmacokinetic Investigations of Antiretroviral agents in HIV-infected pregnant wOmen: physiologically-based predictions and clinical validation), a grant of the Dutch government has been received for the project. PANNA data will be used for validation.

Further collaboration with the IMPAACT group on combining data from both networks, for abstracts or papers.

Angela and David

IMPORTANT: we have a new email address!!!

Angela Colbers
 Project manager
 E-mail: Angela.Colbers@radboudumc.nl
 Radboud university medical center,
 Internal postal code 864, Department of Pharmacy,
 P.O. Box 9101, 6500 HB Nijmegen
 Phone: + 31 (0)24 - 361 64 05
 Fax: + 31 (0)24- 366 87 55